On August 20, SBP GROUP rose 10.33% in regular trading, trading at HK$5.4/share, with turnover of HK$182 million.

The surge was driven by the company's interim results released on August 19, which significantly exceeded market expectations. H1 revenue reached RMB 19.44 billion, up 10.6% year-over-year to a record high, while adjusted net profit attributable to shareholders surged 92.3% to RMB 3.34 billion. Innovative drug and out-licensing revenue totaled RMB 8.79 billion, up 44.3%, now accounting for 45.2% of total revenue. The board declared an interim dividend of HK$0.07 per share, a 40% increase from HK$0.05 in the prior year period.

Alongside the earnings, the company unveiled its new global brand SBP Group, signaling its strategic evolution from a domestic leader to a global innovator. The company also highlighted AI-driven manufacturing improvements that boosted antibody yields by 20% and reduced biologics production costs by 20%. Recent pipeline milestones include NMPA approval for a new lung cancer indication and breakthrough therapy designations for its HER2 ADC candidate.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)